↓ Skip to main content

Heterogeneity of Toll-like receptor 9 signaling in B cell malignancies and its potential therapeutic application

Overview of attention for article published in Journal of Translational Medicine, February 2017
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (63rd percentile)
  • Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

twitter
2 X users
wikipedia
1 Wikipedia page

Citations

dimensions_citation
23 Dimensions

Readers on

mendeley
52 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Heterogeneity of Toll-like receptor 9 signaling in B cell malignancies and its potential therapeutic application
Published in
Journal of Translational Medicine, February 2017
DOI 10.1186/s12967-017-1152-5
Pubmed ID
Authors

Ling Bai, Wei Chen, Jingtao Chen, Wei Li, Lei Zhou, Chao Niu, Wei Han, Jiuwei Cui

Abstract

Toll-like receptor 9 (TLR9) is expressed in a variety of B-cell malignancies and works as a bridge between innate and adaptive immunity. CpG oligodeoxynucleotides (CpG ODNs), TLR9 agonists, are able to induce anticancer immune responses and exert direct effects against cancer cells, serving as cancer therapeutic agents. Therefore, TLR9 might be a potential therapeutic target for drug development. However, several new evidences have revealed that direct effects of TLR9 agonists on B-cell malignancies is controversial. For example, CpG ODNs can induce apoptosis in certain type of chronic lymphocytic leukemia and lymphoma cells, while induce proliferation in multiple myeloma and other types of lymphoma cells. In this review, we summarize current understanding of the heterogeneity in responses of normal and malignant B cells to TLR9 agonists, due to differences in TLR9 expression levels, genetic alterations (such as MyD88 mutation), and signaling pathway activation. Especially, the downstream molecules of NF-κB signaling pathway play an important role in the heterogeneous response. In order to provide possibilities for therapeutic manipulation of TLR9 agonists in the treatment of these disorders, the preclinical and clinical advances in using CpG ODNs alone and in combination therapies are also summarized in this review.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 52 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 52 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 12 23%
Other 7 13%
Student > Master 6 12%
Researcher 6 12%
Student > Bachelor 3 6%
Other 6 12%
Unknown 12 23%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 12 23%
Immunology and Microbiology 9 17%
Medicine and Dentistry 6 12%
Agricultural and Biological Sciences 3 6%
Nursing and Health Professions 2 4%
Other 8 15%
Unknown 12 23%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 April 2022.
All research outputs
#7,415,821
of 24,411,829 outputs
Outputs from Journal of Translational Medicine
#1,184
of 4,363 outputs
Outputs of similar age
#112,741
of 316,192 outputs
Outputs of similar age from Journal of Translational Medicine
#16
of 68 outputs
Altmetric has tracked 24,411,829 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 4,363 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.9. This one has gotten more attention than average, scoring higher than 72% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 316,192 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.
We're also able to compare this research output to 68 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 77% of its contemporaries.